What You Should Know:
– VahatiCor, a medtech company focused on transforming cardiac care secures $23M in Series B funding led by S3 Ventures, with support from Intuitive Ventures and a strategic investor.
– The capital infusion will be used to advance VahatiCor’s SERRA-I early feasibility study (30 subjects across six sites), accelerate engineering development, and prepare the company for crucial pivotal trials.
The Urgent Need: Inadequate Treatment for CMD
The need for new solutions in this area is urgent and significant. Coronary Microvascular Dysfunction (CMD) is a condition affecting an estimated 3–4 million Americans who experience chest pain and angina despite having no blockages in their major coronary arteries.
CMD is a critical public health issue that disproportionately impacts women, who face a 2–4 times increased risk of cardiac events when they have impaired coronary flow. The medical community currently lacks effective treatments: existing medications fail over half of patients, and no current treatments directly improve coronary blood flow.
The A-FLUX Reducer System®: A Novel Device Solution
VahatiCor’s proprietary solution is the A-FLUX Reducer System®. This is a coronary sinus reducer device designed to create controlled narrowing in order to optimize and redistribute oxygenated blood flow.
A key differentiator of the device is its design: it features a repositionable, self-expanding design that offers advantages in procedural safety and efficacy. By directly addressing the underlying flow issues, VahatiCor aims to provide a new therapeutic option for patients who currently have limited choices.
